

Small Molecules

Gefitinib

Tyrosine kinase inhibitor; Inhibits EGFR

Catalog # 73162

500 mg



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713


INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

Gefitinib is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase that binds competitively in the ATP binding pocket with IC_{50} values of 23 and 80 nM for A431 vulval squamous carcinoma cells and KB cells, respectively (Barker et al.).

Molecular Name:	Gefitinib
Alternative Names:	ZD1839; Gefonib
CAS Number:	184475-35-2
Chemical Formula:	$C_{22}H_{24}ClFN_4O_3$
Molecular Weight:	446.9 g/mol
Purity:	≥ 98%
Chemical Name:	N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
Structure:	



Properties

Physical Appearance:	A crystalline solid
Storage:	Product stable at -20°C as supplied. Protect from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com .
Solubility:	· DMSO ≤ 40 mM · Absolute ethanol ≤ 0.7 mM For example, to prepare a 10 mM stock solution in DMSO, resuspend 500 mg in 112 mL of DMSO.

Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.

Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

CANCER RESEARCH

- Blocks proliferation of multiple cancer cell types in vitro and in mouse xenograft models, including colon, ovarian, and breast cancer cell lines (Ciardiello et al.).
- Induces apoptosis in the HaCaT human keratinocyte cell line via a c-Jun N-terminal kinase (JNK) activation, an EGFR-independent mechanism (Lu et al.).

References

- Barker AJ et al. (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. *Bioorg Med Chem Lett* 11(14): 1911–4.
- Ciardiello F et al. (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. *Clin Cancer Res* 6(5): 2053–63.
- Lu P-H et al. (2011) Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. *Br J Dermatol* 164(1): 38–46.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, please visit our website at www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

This product is hazardous. Please refer to the Safety Data Sheet (SDS).

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2017 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.